<DOC>
	<DOCNO>NCT00357591</DOCNO>
	<brief_summary>The Company 's proprietary product base Orqis Medical 's hypothesis , support early clinical data , increase maintain continuous blood flow descend aorta , know continuous aortic flow augmentation CAFA , improve hemodynamics heart failure patient . The clinical impact hemodynamic improvement currently evaluate determine effect CAFA stop reverse progression heart failure three physiological effect : - VASCULAR - Reducing systemic vascular resistance - RENAL - Improving renal function - CARDIAC - Reducing cardiac workload</brief_summary>
	<brief_title>Randomized Trial Patients With Chronic Heart Failure With Acute Decompensation</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Patients hospitalize due decompensated heart failure require IV inotropic and/or vasodilator diuretic therapy 2 . Patients receive appropriate medical therapy heart failure , define ACE inhibitor beta blocker ( unless tolerate contraindicate ) diuretic , 1 month prior study entry 3 . For least 24 hour prior inclusion study , patient treat minimum dose following : dobutamine 2.5μg/kg/min milrinone 0.3μg/kg/min dopamine 5μg/kg/min . nesiritide 0.01μg/kg/min nitroglycerin 0.3 µg/kg/min nitroprusside 0.3 µg/kg/min combination agent , diuretic therapy . Doses state medication stable 6 hour prior inclusion study . An increase dosage within first 8 hour enrollment determine attend physician unlikely follow definition `` respond adequately IV inotropic and/or vasodilator diuretic therapy '' exhibit : PCWP ≥ 20 mmHg time randomization PCWP ≥ 18 mmHg continuously 24 hour PCWP ≥ 20 mmHg continuously 12 hour prior randomization . Cardiac Index &lt; 2.4 L/min/m2 There evidence abnormal renal function and/or diuretic resistance define : Serum creatinine &gt; 1.2 mg/dL Diuretic dosage intravenous Furosemide ≥ 120 mg daily , equivalent 4 . LVEF &lt; 35 % 5 . Male female 1890 year age 6 . If female , childbearing potential negative pregnancy test 7 . Written inform consent 8 . Willingness participate require followup exam 1 . Acute Qwave myocardial infarction within past 7 day 2 . Post cardiotomy shock within past 30 day 3 . Cardiac surgery within past 14 day 4 . Bridge transplant 5 . History severe COPD define FEV1 &lt; 1.0 liter 6 . History malignant arrhythmia define either : sustain ventricular tachycardia &gt; 15 beat length , associate correctable cause , within precede 3 month , unless patient presently implantable cardiac defibrillator . history ventricular fibrillation sudden death , unless patient presently implantable cardiac defibrillator 7 . Patients implanted resynchronization device within previous 14 day possibility implant within 60 day follow randomization 8 . Systolic pressure &lt; 80 mmHg 9 . Requiring cardiopulmonary support type device 10 . Platelets &lt; 50,000/mm3 evidence coagulopathy , INR great 1.5 absence anticoagulation therapy . 11 . Infection ( WBC ≥ 12.5 x 103/ml , temperature ≥ 100.5°F/38°C ) 12 . History cerebral vascular accident ( CVA ) transient ischemic attack ( TIA ) within last 3 month 13 . Unwilling unable receive blood transfusion 14 . Inability undergo treatment heparin 15 . Patients dialysis serum creatinine &gt; 4.0 mg/dl 16 . Primary liver disease bilirubin , SGOT , SGPT &gt; 4X upper limit normal 17 . Life expectancy disease &lt; 12 month 18 . Patients active cardiac transplantation wait list , unless document reason ( large body habitus , highly sensitize , O blood group ) anticipate transplant unlikely within subsequent 65 day . 19 . Symptomatic patent foramen ovale intracardiac shunt 20 . Patients diagnose clinically significant peripheral vascular disease , define absent pedal pulse sign symptom limb ischemia , include history intermittent claudication 21 . Patients amyloidosis , thyroid induce heart failure , high output failure secondary arteriovenous fistula , significant uncorrected primary valvular disease ( exception mitral regurgitation believe secondary LV dilatation )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Acute Decompensation</keyword>
	<keyword>Chronic Heart Failure</keyword>
</DOC>